Registration

HPS GROUP, LLC for RARE DISEASE THERAPEUTICS

Firm
Client
Income
—
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

To provide waivers of product and facility user fees for small companies developing orphan drugs, as considered by HR 2900 and S1082, FDA Reform legislation enacted in 2007

LobbyistCovered position, as disclosed
STEVEN GROSSMAN New Deputy Asst. Secretary for Health, DHHS (1985 to 1989)

Bills named: H.R. 2900 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.